ARTICLE | Clinical News

DB289: Phase I

March 12, 2001 8:00 AM UTC

IMMT said that in a Phase I trial of DB289 in Germany that enrolled 72 volunteers, the product was well tolerated at a dose expected to be effective against PCP. IMMT will begin Phase II trials in PCP...